Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis

Circulation

Volumn 99, Issue 22, 1999, Pages 2871-2875

  Baller, Detlev ^a,b   Notohamiprodjo, Gunawan ^b   Gleichmann, Ulrich ^a   Holzinger, Jens ^b   Weise, Reiner ^b   Lehmann, Joachim ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Atherosclerosis; Coronary flow reserve; Drugs; Hypercholesterolemia; Tomography

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0033536021     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2871     Document Type: Article

References (38)

1. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995; 332:512-521.
2. Zeiher AM, Drexler H, Saurbier H, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest. 1993;92:652-662.
3. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991;84:1984-1992.
4. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation. 1994;90:808-817.
5. Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996;94:3232-3238.
6. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
7. Anderson, TA, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
8. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
9. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing endothelium. Circulation. 1994;89:1530-1538.
10. Campeau L. Grading of angina pectoris. Circulation. 1975;54:522-523.
11. Weise, R, Baller D, Holzinger J, Notohamiprodjo G, Betker S, Montanus H, Lehmann J, Gleichmann U. Relationship between LDL-cholesterol, coronary resistance and flow reserve. Eur J Nucl Med. 1997;24:883. Abstract.
12. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomography imaging. J Am Coll Cardiol. 1990;15:1032-1042.
13. Muzik O, Beanlands R, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med. 1993;34:83-91.
14. Bretschneider HJ, Frank A, Bernard U, Kochsiek K, Scheler F. Die Wirkung eines Pyrimidopyrimidin-Derivates auf die Sauerstoff-Versorgung des Herzmuskels. Arzneimittelforschung. 1959;9:49-59.
15. Holtz J, Krivokuca M, Allgeier J, Goetz RM. Dipyridamole-recruitable coronary reserve is attenuated by suppression of nitric oxide synthesis in rats. Eur Heart J. 1991;12(suppl 4)525. Abstract.
16. Lupi A, Buffon A, Finocchiario M. L, Conti E, Maseri A, Crea F. Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J. 1997;18:614-617.
17. Roubanyi O, Vanhoutte PM. Endothelial-removal decreases relaxations of canine coronary arteries caused by adrenergic agonists and adenosine. J Cardiovasc Pharmacol. 1985;7:139-144.
18. Smits P, Williams SB, Lipson DE, Banitt P, Rongen GA, Creager MA. Endothelial release on nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation. 1995;92:2135-2144.
19. Davis CA III, Sherman AJ, Yaroshenko Y, Harris KR, Hedjbeli S, Parker MA, Klocke FJ. Coronary vascular responsiveness to adenosine is impaired additively by blockade of nitric oxide synthesis and a sulfonylurea. J Am Coll Cardiol. 1998;31:816-822.
20. 2 supply by the DPTI/STTI ratio under maximal coronary dilation. Basic Res Cardiol. 1979;74:378-388.
21. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237-240.
22. Cannon RO III, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation. 1992;85:883-892.
23. Quyyumi AA, Cannon RO III, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation. 1992;86:1864-1871.
24. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664.
25. Reddy KG, Nair NR, Sheehan HM, Hodgson JM. Evidence that endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 1994;23:833-843.
26. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
27. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139-2148.
28. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995;91:2345-2352.
29. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet. 1993;341:1496-1500.
30. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
31. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Physiol. 1995;75:B75-B81.
32. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995;270:319-324.
33. Galle J, Bassenge E, Busse R. Oxidized low-density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res. 1990;66:1287-1293.
34. Drexler H, Zeiher AM, Meinzer K, Just J. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991;338:1546-1550.
35. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation. 1998;98:211-216.
36. Laufs U, La Fata V, Plutzky I, Liao IK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97: 1129-1135.
37. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287-324.
38. Andrews TC, Raby K, Barry J, Cameron L, Naimi BA, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.